RELMADA THERAPEUTICS, INC.: Squadron Capital Management LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Squadron Capital Management LLC amended its Schedule 13G filing on Relmada Therapeutics, Inc., updating its passive stake disclosure with the SEC under accession number 0002050709-26-000032. The amendment signals a change in the investment firm's reported position in the clinical-stage biopharmaceutical company, though the filing summary did not specify the revised share count or ownership percentage. Schedule 13G filings are required of investors holding more than 5% of a company's voting securities and are typically updated when positions shift. The revision matters because it gives investors a fresh look at institutional ownership in Relmada, a name whose shareholder base can influence trading liquidity and sentiment. What to watch next is the full filing detail, which should clarify Squadron's exact stake and whether the change reflects accumulation or reduction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
RELMADA THERAPEUTICS, INC., Squadron Capital Management LLC